Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 27, 2007

BrainCells and Lundbeck Form CNS Collaboration

  • BrainCells formed a research collaboration with H. Lundbeck. The company will use its neurogenesis-based technology to screen central nervous system (CNS) targets and compounds.

    In performing the screening, BrainCells will determine whether or not the targets or compounds promote neurogenesis. Lundbeck will advance the appropriate targets or compounds through development.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »